The Vaccine Book, Second Edition provides comprehensive information on the current and future state of vaccines. It reveals the scientific opportunities and potential impact of vaccines, including economic and ethical challenges, problems encountered when producing vaccines, how clinical vaccine trials are designed, and how to introduce vaccines into widespread use.
Although vaccines are now available for many diseases, there are still challenges ahead for major diseases, such as AIDS, tuberculosis, and malaria. This book is designed for students, researchers, public health officials, and all others interested in increasing their understanding of vaccines. It answers common questions regarding the use of vaccines in the context of a rapidly expanding anti-vaccine environment.
This new edition is completely updated and revised with new and unique topics, including new vaccines, problems of declining immunization rates, trust in vaccines, the vaccine hesitancy, and the social value of vaccines for the community vs. the individual child's risk.
- Provides insights into diseases that could be prevented, along with the challenges facing research scientists in the world of vaccines
- Gives new ideas about future vaccines and concepts
- Introduces new vaccines and concepts
- Gives ideas about challenges facing public and private industrial investors in the vaccine area
- Discusses the problem of declining immunization rates and vaccine hesitancy
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Part I: Understanding Vaccine Impact at Population and Individual Levels
Chapter 1: The Impact of Vaccination on the Epidemiology of Infectious Diseases
Chapter 2: How Vaccines Work
Part II: How to Design, Assess and Produce Vaccines
Chapter 3: Vaccine Design in the 21st Century
Chapter 4: Vaccine Adjuvants
Chapter 5: Vaccine Production: Main Steps and Considerations
Chapter 6: How are Vaccines Assessed in Clinical Trials?
Chapter 7: Immunological Correlates of Vaccine-Mediated Protection
Part III: Vaccine Safety
Chapter 8: How Vaccine Safety is Monitored
Chapter 9: Vaccination and Autoimmune Diseases
Part IV: New Vaccination Strategies
Chapter 10: Maternal Immunization: Protecting Vulnerable Populations
Chapter 11: New Challenges for Pertussis Vaccines
Part V: Recently Introduced Vaccines
Chapter 12: Pneumococcus, Pneumococcal Disease, and Prevention
Chapter 13: Human Papillomavirus Vaccines
Chapter 14: Rotavirus Vaccines
Part VI: New Approaches for Needed Vaccines
Chapter 15: Antiviral Vaccines: Challenges and Advances
Chapter 16: New Approaches for Needed Vaccines: Bacteria
Chapter 17: Vaccines Against Parasites
Part VII: Major Global Vaccine Challenges
Chapter 18: Tuberculosis Vaccines
Chapter 19: Major Global Vaccine Challenges: Recent Progress in Malaria Vaccine Development
Chapter 20: AIDS Vaccines
Chapter 21: Influenza Vaccines and Vaccination Strategies
Part VIII: Ethical Considerations
Chapter 22: Ethical Considerations in Vaccine Trials in Resource-Limited Settings
Part IX: Vaccine Economics
Chapter 23: Economic Considerations for the Development of Global Vaccines: a Perspective From the Vaccine Industry
Chapter 24: Introduction of Vaccines Into National Programs
Chapter 25: Transitioning Immunization Into the Health Care System: Strengthening Routine Immunization in India
Part X: Trust in Vaccines
Chapter 26: Vaccine Acceptance
Chapter 27: Trust and Confidence in Vaccines: Tales of Three Vaccines, Lessons for Others
Part XI: Future Challenges
Chapter 28: Vaccines for Emerging Viral Diseases
Chapter 29: Cancer Immunotherapy by Checkpoint Blockade
Chapter 30: Adoptive Cellular Therapy With Synthetic T Cells as an "Instant Vaccine for Cancer and Immunity
Dr. Bloom is Harvard University's Distinguished Service Professor of the Department of Immunology and Infectious Diseases and Former Dean of the Harvard School of Public Health. He received a bachelor's degree and an honorary Sc.D. from Amherst College, and a Ph.D. from Rockefeller University. He is widely recognized for his work in the area of cell-mediated immunity, infectious diseases, particularly tuberculosis and leprosy, and global health. The discovery of lymphocyte-produced cytokines and the development of genetic systems in mycobacteria are among his scientific contributions. He has published over 300 papers and edited 4 books. He served as a consultant to the White House on International Health Policy, was elected President of the American Association of Immunologists, and served as President of the Federation of American Societies for Experimental Biology.
Dr. Bloom has been extensively involved with the World Health Organization (WHO) for more than 40 years. He was a member of the WHO Advisory Committee on Health Research (ACHR) and chaired the WHO Committees on Immunology of Leprosy (IMMLEP), Immunology of Tuberculosis (IMMTUB), the Scientific and Technical Advisory Committee of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (STAC) and chaired the WHO Global Malaria Programme. He was first chair of the Board of Trustees of the International Vaccine Institute, Seoul, Korea. He as served on the National Advisory Councils of the U.S. National Institute of Allergy and Infectious Diseases, NIH, and the Center for Infectious Diseases, of the US Centers for Disease Control and Prevention. He currently serves on the scientific advisory boards of the Wellcome Trust Centre for Human Genetics, K-RITH, and Human Heredity and Health in Africa (H3Africa). He has received numerous awards for his scientific work including the first Bristol-Myers Award in Infectious Diseases, the Robert Koch Gold Medal for lifetime achievement in research, and shared the Novartis Award in Immunology. He was elected to membership of the U.S. National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society.Lambert, Paul-Henri
Paul-Henri Lambert, MD, is now associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is particularly interested in vaccination strategies and evaluation of adverse effects. He is directing the International Advanced Course of Vaccinology (ADVAC) organized under the auspices of the Fondation Mérieux and University of Geneva. He is a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI) and past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the WHO GACVS (Global Advisory Committee on Vaccine Safety). Paul Henri Lambert is a native of Belgium where he was boarded in Internal Medicine (University of Liege). He joined Frank Dixon at Scripps Institute, La Jolla, California, for his training then moved to University of Geneva Medical School where he became professor in the Departments of Medicine and of Pathology. His research activities lead him to decipher immunological mechanisms involved in autoimmune and immune complex-mediated diseases, in the pathogenesis of malaria and in new strategies to optimize vaccine immunogenicity. In 1987, he was appointed as chief Microbiology and Immunology at the World Health Organization and in 1994, Chief, Vaccine Research and Development, WHO Global Program for Vaccines and Immunization. He was then deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries. Paul-Henri Lambert is author or co-author of 436 publications, member of several international scientific boards, foreign member of the Royal Academy of Medicine in Belgium and Fellow of the American Association for the Advancement of Science.